Celltrion, Inc. Stock Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
Jun. 07 | Celltrion's Avastin Biosimilar Gains 12% Market Share in Japan | MT |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Sales 2024 * | 3,485B 2.53B | Sales 2025 * | 4,155B 3.02B | Capitalization | 39,636B 28.78B |
---|---|---|---|---|---|
Net income 2024 * | 540B 392M | Net income 2025 * | 1,100B 799M | EV / Sales 2024 * | 11.6 x |
Net Debt 2024 * | 721B 523M | Net cash position 2025 * | 106B 76.6M | EV / Sales 2025 * | 9.51 x |
P/E ratio 2024 * |
76
x | P/E ratio 2025 * |
37
x | Employees | - |
Yield 2024 * |
0.23% | Yield 2025 * |
0.25% | Free-Float | 66.01% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
1st Jan change | Capi. | |
---|---|---|
+49.21% | 56.87B | |
+39.98% | 39.72B | |
-6.86% | 39.27B | |
+12.00% | 26.21B | |
-18.27% | 19.79B | |
+29.57% | 12.28B | |
+25.41% | 12.23B | |
-0.35% | 12.12B | |
-10.99% | 10.84B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock